Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

NCT05289856 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

DRUG: combination of Avelumab and Cabozantinib

Sponsor

Johannes Gutenberg University Mainz

Collaborators

[object Object]
[object Object]